

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2013-05-20** | Period of Report: **2013-05-10**
SEC Accession No. [0001140361-13-021757](#)

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

BLANCHE WILLARD R JR

CIK: **1577068**

Type: **3** | Act: **34** | File No.: **000-19271** | Film No.: **13857198**

Mailing Address
*ONE IDEXX DRIVE
WESTBROOK ME 04092*

ISSUER

IDEXX LABORATORIES INC /DE

CIK: **874716** | IRS No.: **010393723** | State of Incorporation: **DE** | Fiscal Year End: **1231**
SIC: **2835** In vitro & in vivo diagnostic substances

Mailing Address
*ONE IDEXX DRIVE
WESTBROOK ME
04092-2041*

Business Address
*ONE IDEXX DRIVE
WESTBROOK ME
04092-2041
2075560300*

FORM 3**UNITED STATES SECURITIES AND
EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: 02/28/2011
 Estimated average burden
 hours per response 0.5

**INITIAL STATEMENT OF BENEFICIAL
OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the
 Investment Company Act of 1940

1. Name and Address of Reporting Person <u>BLANCHE WILLARD R JR</u> (Last) (First) (Middle) <u>ONE IDEXX DRIVE</u> (Street) <u>WESTBROOK, ME 04092</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/ Year) <u>05/10/2013</u>	3. Issuer Name and Ticker or Trading Symbol <u>IDEXX LABORATORIES INC /DE [IDXX]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner <input checked="" type="checkbox"/> Officer (give title _____ Other (specify below) below) <u>CHIEF FINANCIAL OFFICER</u> 5. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person _____ Form Filed by More than One Reporting Person
---	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,698 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/ Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Unit	(2)	(2)	Common Stock	121	(2)	D	
Restricted Stock Unit	(3)	(3)	Common Stock	185	(3)	D	
Incentive Stock Option (right to buy)	(4)	02/13/2017	Common Stock	1,489	(4)	D	
Restricted Stock Unit	(5)	(5)	Common Stock	225	(5)	D	
Incentive Stock Option (right to buy)	(6)	02/13/2018	Common Stock	1,170	(6)	D	
Restricted Stock Unit	(7)	(7)	Common Stock	269	(7)	D	
Incentive Stock Option (right to buy)	(8)	02/13/2019	Common Stock	1,119	(8)	D	
Restricted Stock Unit	(9)	(9)	Common Stock	547	(9)	D	
Incentive Stock Option (right to buy)	(10)	02/13/2020	Common Stock	1,888	(10)	D	

Explanation of Responses:

1. Includes 847 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on the last business day of each calendar quarter beginning on 6/30/2008 through 3/29/2013.
2. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2010) of the date of grant.
3. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2011) of the date of grant.
4. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2011) of the date of grant.
5. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2012) of the date of grant.
6. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2012) of the date of grant.
7. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2013) of the date of grant.
8. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2013) of the date of grant.
9. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2014) of the date of grant.
10. Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2014) of the date of grant.

Signatures

[Ann E. Nolan, Attorney-in-Fact for Willard R. Blanche, Jr.](#)

** Signature of Reporting Person

[05/20/2013](#)

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.